Segmentation, Major Trends, and Competitive Overview of the Diabetic Retinopathy Market

The diabetic retinopathy market is on track for significant expansion as advancements in technology and growing healthcare needs continue to shape its future. With increasing awareness of eye health and innovative treatment options, this sector is poised for considerable growth and transformation by 2030. Let's explore the predicted market size, key players, emerging trends, and the detailed market segments driving this evolution.

Forecasted Market Size and Growth of the Diabetic Retinopathy Market
The diabetic retinopathy market is projected to experience robust growth, reaching a value of $13.54 billion by 2030. This represents a compound annual growth rate (CAGR) of 8.0% over the coming years. Factors contributing to this expansion include the rising use of AI-assisted screening tools, the growth of ophthalmology clinics, wider adoption of anti-VEGF therapies, increased focus on preventive eye care, and the growing population of aging diabetic patients. Key trends expected to influence this market through the forecast period involve more widespread retinal screening programs, enhanced use of anti-VEGF treatments, improved early detection and monitoring methods, the growing integration of AI-based retinal imaging, and a stronger emphasis on preserving vision.

Download a free sample of the diabetic retinopathy market report:
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Entities Driving the Diabetic Retinopathy Industry
Several prominent companies play pivotal roles in the diabetic retinopathy market. These include Pfizer Inc., F-Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, and Clearside Biomedical Inc.

Notable Industry Acquisitions Enhancing Market Strength
In an important development in January 2025, the US-based biotech firm Regeneron Pharmaceuticals Inc. acquired Oxular Limited, a UK biotechnology company focused on long-acting drug formulations and targeted retinal therapies. Although the acquisition amount was not disclosed, Regeneron's purchase grants it access to Oxular's proprietary sustained-release Oxuspheres technology and the Oxulumis suprachoroidal microcatheter delivery system. This strategic move is set to bolster Regeneron's retinal drug delivery capabilities while expanding its operational scale and therapeutic impact in ophthalmic care. Oxular is known for its lead candidate OXU-001 and its integrated drug-device platform aimed at treating posterior-segment eye disorders.

The diabetic retinopathy market is on track for significant expansion as advancements in technology and growing healthcare needs continue to shape its future. With increasing awareness of eye health and innovative treatment options, this sector is poised for considerable growth and transformation by 2030. Let's explore the predicted market size, key players, emerging trends, and the detailed market segments driving this evolution.

Forecasted Market Size and Growth of the Diabetic Retinopathy Market
The diabetic retinopathy market is projected to experience robust growth, reaching a value of $13.54 billion by 2030. This represents a compound annual growth rate (CAGR) of 8.0% over the coming years. Factors contributing to this expansion include the rising use of AI-assisted screening tools, the growth of ophthalmology clinics, wider adoption of anti-VEGF therapies, increased focus on preventive eye care, and the growing population of aging diabetic patients. Key trends expected to influence this market through the forecast period involve more widespread retinal screening programs, enhanced use of anti-VEGF treatments, improved early detection and monitoring methods, the growing integration of AI-based retinal imaging, and a stronger emphasis on preserving vision.

Download a free sample of the diabetic retinopathy market report:
https://www.thebusinessresearchcompany.com/report/diabetic-retinopathy-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Apr_PR
Leading Entities Driving the Diabetic Retinopathy Industry
Several prominent companies play pivotal roles in the diabetic retinopathy market. These include Pfizer Inc., F-Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc., Genentech Inc., Santen Pharmaceutical Co Ltd., Carl Zeiss Meditec AG, Lumenis Ltd., Optos Plc., Quantel Medical SAS, NIDEK Co Ltd., IRIDEX Corporation, Alimera Science Inc., Oxurion NV, EyePoint Pharmaceuticals, Opthea Limited, KalVista Pharmaceuticals Inc., Regenxbio Inc., Kodiak Sciences Inc., Oculis, Verseon International Corporation, and Clearside Biomedical Inc.

Notable Industry Acquisitions Enhancing Market Strength
In an important development in January 2025, the US-based biotech firm Regeneron Pharmaceuticals Inc. acquired Oxular Limited, a UK biotechnology company focused on long-acting drug formulations and targeted retinal therapies. Although the acquisition amount was not disclosed, Regeneron's purchase grants it access to Oxular's proprietary sustained-release Oxuspheres technology and the Oxulumis suprachoroidal microcatheter delivery system. This strategic move is set to bolster Regeneron's retinal drug delivery capabilities while expanding its operational scale and therapeutic impact in ophthalmic care. Oxular is known for its lead candidate OXU-001 and its integrated drug-device platform aimed at treating posterior-segment eye disorders.

Emerging Trends Shaping the Future of Diabetic Retinopathy Market
Innovations in the broader medical diagnostics field are influencing the diabetic retinopathy market as well. For example, companies are developing advanced products like coronary heart disease (CHD) detection tests to boost customer reach and revenue. CHD tests help identify artery blockages affecting the heart, thereby improving patient outcomes.

Highlighting such innovation, in August 2023, Cardio Diagnostics Holdings Inc., a US biotech company, launched PrecisionCHD. This blood-based test uniquely combines epigenetic and genetic biomarkers with artificial intelligence to detect coronary heart disease. The procedure requires only a simple blood sample collected either at the doctor's office or at home and uses a laboratory technique comparable to COVID-19 testing. Results are delivered within just 10 business days, providing a faster and more convenient alternative to traditional CHD detection tools like stress echocardiograms. These kinds of breakthroughs demonstrate how AI and biomarker integration are advancing diagnostics, which is relevant to the diabetic retinopathy market as well.

Core Segments Covered in the Diabetic Retinopathy Market Report
The diabetic retinopathy market is analyzed through several critical segments:

1) By Type:
- Proliferative Diabetic Retinopathy (PDR)
- Non-Proliferative Diabetic Retinopathy (NPDR)

2) By Treatment:
- Anti-VEGF Drugs
- Intraocular Steroid Injection
- Laser Photocoagulation
- Vitreoretinal Surgery

3) By End-User:
- Hospitals
- Ambulatory Surgical Centers
- Other End Users

Further subcategories include:
- Proliferative Diabetic Retinopathy (PDR) subtypes such as Neovascularization, Vitreous Hemorrhage, and Tractional Retinal Detachment.
- Non-Proliferative Diabetic Retinopathy (NPDR) subtypes including Mild, Moderate, and Severe NPDR.

This segmentation provides an in-depth perspective on the various forms of diabetic retinopathy, treatment approaches, and the healthcare settings where these therapies are applied, giving a comprehensive outlook on the market's structure and dynamics.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.